Muscle-Sparing Fat Loss: A Chattanooga Physician on Losing Fat Without Losing Muscle

I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health. I read every patient chart myself. When someone loses 40 pounds on a GLP-1 medication, my job is not just to celebrate the number on the scale — it is to make sure that number came off the right place. Because not all weight loss is created equal, and the difference matters more than most programs will ever tell you.

Why “Muscle-Sparing Fat Loss” Is the Right Question

When you lose weight by any method — diet, surgery, or medication — some of what you lose is fat and some is lean mass: muscle, organ tissue, and bone. That has always been true. With the current GLP-1 medications, the published body-composition literature suggests that roughly 25 to 35 percent of the weight lost can come from lean mass when the loss is rapid and unmanaged (body-composition data summarized across semaglutide and tirzepatide trials; individual results vary). That is not a reason to fear these drugs. It is a reason to use them under someone who is watching.

Why does it matter? Muscle is metabolically active tissue. It is where you burn calories at rest, it is what keeps you strong and upright as you age, and — this is the part patients rarely hear — losing it makes the rebound worse. Lose muscle on the way down, and your body burns fewer calories at your new weight, which is exactly what makes regaining easier. Protecting lean mass is not vanity. It is the mechanism of lasting results.

The Frontier: Drugs That Target Muscle Directly

This is where the science is genuinely exciting. A new class of agents is being studied specifically to redirect weight loss away from muscle and toward fat. The most advanced is bimagrumab — a monoclonal antibody that blocks the activin type II receptors on muscle. In plain terms, it takes the brakes off muscle growth while the body mobilizes fat.

The early signal is striking. In the Phase 2b BELIEVE trial (507 adults, 72 weeks), bimagrumab combined with semaglutide produced about 22.1 percent total weight loss — but the composition of that loss is the headline. About 92.8 percent of the weight lost came from fat, compared with roughly 71.5 percent on semaglutide alone, and lean mass fell only about 2.9 percent versus about 7.4 percent on semaglutide alone (Heymsfield SB et al, BELIEVE Phase 2b, Nature Medicine 2026, PMID 41772149). Visceral fat — the dangerous fat around your organs — dropped about 58 percent versus 36 percent. As a single agent in an earlier study, bimagrumab actually increased lean mass by about 3.6 percent while cutting fat mass roughly 20.5 percent (Heymsfield SB et al, JAMA Network Open 2021, PMID 33439265). Trial averages, not promises — individual results vary.

What This Frontier Actually Teaches Us

Here is the lesson I take from the bimagrumab data, and I want my Chattanooga patients to take it too: the future of weight loss is not about losing more — it is about losing better. The drugs in development are essentially trying to engineer, at the molecular level, the same outcome a good physician already aims for with the tools we have now: keep the fat loss, protect the muscle, target the visceral fat.

You do not have to wait three years for an investigational antibody to get most of that benefit. The two biggest levers for protecting muscle during weight loss are already in your hands today — adequate protein and resistance training — and they work in the same direction these drugs are being designed to push. What matters is whether anyone is actually building them into your plan.

What I Do for Patients in Chattanooga Today

At Summit, muscle protection is not an afterthought I mention if you ask. It is built into the protocol from your first visit, alongside the medication itself.

This is the difference between a physician-led program and a refill mill. A questionnaire scored by software cannot tell whether the weight leaving your body is fat or muscle. It cannot adjust your dose when it sees the wrong thing happening. I can, because I read your chart and I watch the trend — not just the number, but where the number is coming from.

There is one more reason this fits Summit specifically. We build an exit strategy into every plan — the goal is to get you to your weight and then taper the medication. Lean mass is what makes that exit hold. Protect your muscle on the way down, and your metabolism is in a far stronger position to keep the weight off once you come off the drug. That is the whole point.

The Bottom Line for Chattanooga

Muscle-sparing fat loss is the most important shift in obesity medicine right now, and the drugs being engineered to deliver it are worth following. But the principle behind them is already actionable in Tennessee today: lose fat, keep muscle, and do it under a physician who is tracking the difference. If you have lost weight before and watched it come roaring back, the loss of muscle may be a bigger part of that story than anyone ever told you.

You can apply in about five minutes at summitmetabolichealth.com/apply. I personally review every application and reach out — no algorithms, no sales calls.